Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genexine Raises New Funds To Progress Promising HPV, Other Projects

This article was originally published in PharmAsia News

Executive Summary

South Korean bioventure Genexine is on track to meet its goal of progressing and expanding this year the clinical development of its leading assets - orphan disease drugs and cancer immunotherapies. The company now plans to raise new funds via share and bond issues to domestic and overseas investors including its Chinese strategic alliance partner Tasly.

You may also be interested in...



Genexine Edges Ahead In Pediatric GHD After Versartis Trial Failure

Versartis's failure in a Phase III study of somavaratan places Genexine's GX-H9 in a favorable position to become the best-in-class long-acting growth hormone for pediatric growth hormone deficiency.

Inovio Strikes First Partnership, In Emerging Markets, For Lead Product

Inovio's new licensing deal for its most advanced pipeline asset gives the US firm not only its first partner for the cervical dysplasia vaccine but also a presence in a major emerging market.

New Funding To Give ViroMed ‘Favorable Position’ For Gene Therapy Deal

ViroMed joins a group of South Korean bioventures launching share offerings to fund R&D activities, in its case to beef up the clinical data package for its lead project VM202, which should in turn help with a licensing out deal for the gene therapy.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL055695

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel